APA (7th ed.) Citation

LL, B., AJ, P., CR, R., J, K., SM, C., M, F., . . . BL, M. (2021). Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leukemia & lymphoma, 62(9), 2184. https://doi.org/10.1080/10428194.2021.1907378

Chicago Style (17th ed.) Citation

LL, Benitez, et al. "Multicenter Comparison of High-dose Cytarabine-based Regimens Versus Liposomal Daunorubicin and Cytarabine (CPX-351) in Patients with Secondary Acute Myeloid Leukemia." Leukemia & Lymphoma 62, no. 9 (2021): 2184. https://doi.org/10.1080/10428194.2021.1907378.

MLA (9th ed.) Citation

LL, Benitez, et al. "Multicenter Comparison of High-dose Cytarabine-based Regimens Versus Liposomal Daunorubicin and Cytarabine (CPX-351) in Patients with Secondary Acute Myeloid Leukemia." Leukemia & Lymphoma, vol. 62, no. 9, 2021, p. 2184, https://doi.org/10.1080/10428194.2021.1907378.